Brii Biosciences and the Joincare Pharmaceutical Group have joined forces in a groundbreaking partnership. The two companies recently inked a significant license and technology transfer agreement, focusing on BRII-693. This cutting-edge synthetic lipopeptide is specifically tailored to combat multidrug-resistant (MDR) and extensively drug-resistant (XDR) gram-negative bacterial infections.
This strategic alliance entails granting Joincare Group exclusive rights within the Greater China region to spearhead the research, development, and commercialization of BRII-693. The collaboration brings together Brii Bio’s innovative pharmaceutical expertise with Joincare Group’s established foothold in manufacturing and marketing hospital antibiotics.
Dr. Zhi Hong, Chairman, and CEO of Brii Biosciences highlighted the urgency posed by antimicrobial resistance in Greater China. He emphasized the pressing need for novel hospital antibiotics to address this escalating threat effectively. Dr. Hong expressed confidence in Joincare Group as the ideal partner to expedite the progress of BRII-693 from development stages to reaching patients grappling with life-threatening infections.
“This partnership enables us to deliver critical care medicine to Chinese patients facing life-threatening infections,”
stated Dr. Zhi Hong.
The agreement encompasses an initial upfront payment for Brii Bio, coupled with subsequent payments linked to developmental milestones, sales achievements, and tiered royalties based on product sales performance. This financial structure underscores the commitment of both entities towards advancing healthcare solutions that meet critical unmet needs.
Joincare Group CEO Nanqi Lin echoed Dr. Hong’s sentiments about this landmark collaboration empowering their strategic focus in combating infectious diseases effectively.
“This collaboration further strengthened Joincare Group’s strategic positioning in the anti-infection disease area,”
remarked Nanqi Lin.
BRII-693 embodies refined structural modifications derived from polymyxin scaffolds designed to enhance antibacterial efficacy while mitigating toxicity concerns associated with conventional polymyxin agents like renal and neuro-toxicities.
During its preliminary clinical evaluations conducted through Phase I trials, BRII-693 demonstrated promising safety profiles alongside satisfactory tolerability levels among healthy participants. The encouraging results paved the way for Brii Bio to secure approval from regulatory bodies such as China’s National Medical Products Administration (NMPA). This approval greenlights further studies including a Phase I pharmacokinetic bridging study aimed at supporting forthcoming Phase III registration efforts targeting patients afflicted by hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia.
The collaborative efforts between Brii Biosciences and Joincare Pharmaceutical Group mark a pivotal moment in combating antimicrobial resistance challenges through innovative pharmaceutical solutions tailored for specific regional needs while laying a solid foundation for future advancements in global healthcare initiatives.
Leave feedback about this